NEW YORK – Fluidigm reported after the close of the market on Thursday that its first quarter revenues declined 8 percent year over year as both its mass cytometry and microfluidics research product sales were negatively impacted by the COVID-19 pandemic.
For the three months ended March 31, 2020, Fluidigm reported revenues of $27.6 million compared to $30.1 million a year ago and short of analysts' average estimate of $29.0 million.